Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Cancer Chemoprevention
share announcement

Advances in Cancer Chemoprevention

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 July 2012) | Viewed by 29980

Special Issue Editor

Prof. Dr. Ross McKinnon

E-Mail Website
Guest Editor
Flinders Centre for Innovation in Cancer, School of Medicine Flinders University, Sturt Road, Bedford Park, Australia
Interests: pharmacy; clinical pharmacology; cancer biology oncology; glucuronosy; transferase 5ugt

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

28 pages, 3441 KiB  
Article
Preclinical Cancer Chemoprevention Studies Using Animal Model of Inflammation-Associated Colorectal Carcinogenesis
by Takuji Tanaka
Cancers 2012, 4(3), 673-700; https://doi.org/10.3390/cancers4030673 - 16 Jul 2012
Cited by 15 | Viewed by 10049
Abstract
Inflammation is involved in all stages of carcinogenesis. Inflammatory bowel disease, such as ulcerative colitis and Crohn’s disease is a longstanding inflammatory disease of intestine with increased risk for colorectal cancer (CRC). Several molecular events involved in chronic inflammatory process are reported to [...] Read more.
Inflammation is involved in all stages of carcinogenesis. Inflammatory bowel disease, such as ulcerative colitis and Crohn’s disease is a longstanding inflammatory disease of intestine with increased risk for colorectal cancer (CRC). Several molecular events involved in chronic inflammatory process are reported to contribute to multi-step carcinogenesis of CRC in the inflamed colon. They include over-production of free radicals, reactive oxygen and nitrogen species, up-regulation of inflammatory enzymes in arachidonic acid biosynthesis pathway, up-regulation of certain cytokines, and intestinal immune system dysfunction. In this article, firstly I briefly introduce our experimental animal models where colorectal neoplasms rapidly develop in the inflamed colorectum. Secondary, data on preclinical cancer chemoprevention studies of inflammation-associated colon carcinogenesis by morin, bezafibrate, and valproic acid, using this novel inflammation-related colorectal carcinogenesis model is described. Full article
(This article belongs to the Special Issue Advances in Cancer Chemoprevention)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 575 KiB  
Review
The Role of Cyclic Nucleotide Signaling Pathways in Cancer: Targets for Prevention and Treatment
by Alexandra M. Fajardo, Gary A. Piazza and Heather N. Tinsley
Cancers 2014, 6(1), 436-458; https://doi.org/10.3390/cancers6010436 - 26 Feb 2014
Cited by 172 | Viewed by 13029
Abstract
For more than four decades, the cyclic nucleotides cyclic AMP (cAMP) and cyclic GMP (cGMP) have been recognized as important signaling molecules within cells. Under normal physiological conditions, cyclic nucleotides regulate a myriad of biological processes such as cell growth and adhesion, energy [...] Read more.
For more than four decades, the cyclic nucleotides cyclic AMP (cAMP) and cyclic GMP (cGMP) have been recognized as important signaling molecules within cells. Under normal physiological conditions, cyclic nucleotides regulate a myriad of biological processes such as cell growth and adhesion, energy homeostasis, neuronal signaling, and muscle relaxation. In addition, altered cyclic nucleotide signaling has been observed in a number of pathophysiological conditions, including cancer. While the distinct molecular alterations responsible for these effects vary depending on the specific cancer type, several studies have demonstrated that activation of cyclic nucleotide signaling through one of three mechanisms—induction of cyclic nucleotide synthesis, inhibition of cyclic nucleotide degradation, or activation of cyclic nucleotide receptors—is sufficient to inhibit proliferation and activate apoptosis in many types of cancer cells. These findings suggest that targeting cyclic nucleotide signaling can provide a strategy for the discovery of novel agents for the prevention and/or treatment of selected cancers. Full article
(This article belongs to the Special Issue Advances in Cancer Chemoprevention)
►▼ Show Figures

Figure 1

15 pages, 506 KiB  
Review
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
by Rakhshanda Layeequr Rahman and Sandhya Pruthi
Cancers 2012, 4(4), 1146-1160; https://doi.org/10.3390/cancers4041146 - 29 Oct 2012
Cited by 9 | Viewed by 6261
Abstract
Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high risk women [...] Read more.
Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high risk women who may be eligible for chemoprevention. It is prudent that physicians utilize a shared decision approach when counseling high risk women about their preventive options. Barriers and misperceptions however exist with patient and physician acceptance of chemoprevention and continue to impede uptake of chemoprevention as a strategy to reduce breast cancer risk. Programs to increase awareness and elucidate the barriers are critical for women to engage in cancer prevention and promote chemoprevention adherence. Full article
(This article belongs to the Special Issue Advances in Cancer Chemoprevention)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop